Deguelin inhibits the proliferation of human multiple myeloma cells by inducing apoptosis and G2/M cell cycle arrest: Involvement of Akt and p38 MAPK signalling pathway

1S. Gandolfi, J. P. Laubach, T. Hideshima, D. Chauhan, K. C. Anderson and P. G. Richardson, The proteasome and proteasome inhibitors in multiple myeloma, Cancer Metastasis Rev. 36(4) (2017) 561–584; https://doi.org/10.1007/s10555-017-9707-8Search in Google Scholar

2M. Diaz-delCastillo, A. D. Chantry, M. A. Lawson and A. M. Heegaard, Multiple myeloma – A painful disease of the bone marrow, Semin. Cell Dev. Biol. 112 (2021) 49–58; https://doi.org/10.1016/j.semcdb.2020.10.006Search in Google Scholar

3E. S. Ring, M. A. Lawson, J. A. Snowden, I. Jolley and A. D. Chantry, New agents in the treatment of myeloma bone disease, Calcif. Tissue Int. 102(2) (2018) 196–209; https://doi.org/10.1007/s00223-017-0351-7Search in Google Scholar

4F. Marofi, S. Tahmasebi, H. S. Rahman, D. Kaigorodov, A. Markov, A. V. Yumashev, N. Shomali, M. S. Chartrand, Y. Pathak, R. N. Mohammed, M. Jarahian, R. Motavalli and F. Motavalli Khiavi, Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism, Stem Cell Res. Ther. 12(1) (2021) Article ID 217 (21 pages); https://doi.org/10.1186/s13287-021-02283-zSearch in Google Scholar

5B. Noel, S. K. Singh, J. W. Lillard, Jr. and R. Singh, Role of natural compounds in preventing and treating breast cancer, Front Biosci. 12(1) (2020) 137–160; https://doi.org/10.2741/S544Search in Google Scholar

6M. Ezzati, B. Yousefi, K. Velaei and A. Safa, A review on anti-cancer properties of quercetin in breast cancer, Life Sci. 248 (2020) Article ID 117463; https://doi.org/10.1016/j.lfs.2020.117463Search in Google Scholar

7Y. Wang, W. Ma and W. Zheng, Deguelin, a novel anti-tumorigenic agent targeting apoptosis, cell cycle arrest and anti-angiogenesis for cancer chemoprevention, Mol. Clin. Oncol. 1(2) (2013) 215–219; https://doi.org/10.3892/mco.2012.36Search in Google Scholar

8Y. Baba and Y. Kato, Deguelin, a novel anti-tumorigenic agent in human esophageal squamous cell carcinoma, EBioMedicine 26 (2017) 10; https://doi.org/10.1016/j.ebiom.2017.11.010Search in Google Scholar

9X. D. Xu, Y. Zhao, M. Zhang, R. Z. He, X. H. Shi, X. J. Guo, C. J. Shi, F. Peng, M. Wang, M. Shen, X. Wang, X. Li and R. Y. Qin, Inhibition of autophagy by deguelin sensitizes pancreatic cancer cells to doxorubicin, Int. J. Mol. Sci. 18(2) (2017) Article ID 370 (13 pages); https://doi.org/10.3390/ijms18020370Search in Google Scholar

10X. H. Peng, P. Karna, R. M. O’Regan, X. Liu, R. Naithani, R. M. Moriarty, W. C. Wood, H. Y. Lee and L. Yang, Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells, Mol. Pharmacol. 71(1) (2007) 101–111; https://doi.org/10.1124/mol.106.027367Search in Google Scholar

11G. Murillo, X. Peng, K. E. Torres and R. G. Mehta, Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway, Cancer Prev. Res. 2(11) (2009) 942–950; https://doi.org/10.1158/1940-6207.CAPR-08-0232Search in Google Scholar

12T. Yi, H. Li, X. Wang and Z. Wu, Enhancement radiosensitization of breast cancer cells by deguelin, Cancer Biother. Radiopharm. 23(3) (2008) 355–362; https://doi.org/10.1089/cbr.2007.0452Search in Google Scholar

13E. B. Kurutas, The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: current state, Nutr. J. 15(1) (2016) Article ID 71 (22 pages); https://doi.org/10.1186/s12937-016-0186-5Search in Google Scholar

14K. A. Kang, M. J. Piao, Y. S. Ryu, Y. J. Hyun, J. E. Park, K. Shilnikova, A. X. Zhen, H. K. Kang, Y. S. Koh, Y. J. Jeong and J. W. Hyun, Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells, Int. J. Oncol. 51(4) (2017) 1169–1178; https://doi.org/10.3892/ijo.2017.4091Search in Google Scholar

15S. Deng, M. K. Shanmugam, A. P. Kumar, C. T. Yap, G. Sethi and A. Bishayee, Targeting autophagy using natural compounds for cancer prevention and therapy, Cancer 125(8) (2019) 1228–1246; https://doi.org/10.1002/cncr.31978Search in Google Scholar

16A. Lichota and K. Gwozdzinski, Anticancer activity of natural compounds from plant and marine environment, Int. J. Mol. Sci. 19(11) (2018); Article ID 3533 (38 pages); https://doi.org/10.3390/ijms19113533Search in Google Scholar

17A. J. Robles, S. Cai, R. H. Cichewicz and S. L. Mooberry, Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer, Breast Cancer Res. Treat. 157(3) (2016) 475–488; https://doi.org/10.1007/s10549-016-3841-9Search in Google Scholar

18L. Chen, K. Jiang, H. Chen, Y. Tang, X. Zhou, Y. Tan, Y. Yuan, Q. Xiao and K. Ding, Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway, Cancer Manag. Res. 11 (2019) 95–105; https://doi.org/10.2147/CMAR.S169476Search in Google Scholar

19W. Kang, X. Zheng, P. Wang and S. Guo, Deguelin exerts anticancer activity of human gastric cancer MGC-803 and MKN-45 cells in vitro, Int. J. Mol. Med. 41(6) (2018) 3157–3166; https://doi.org/10.3892/ijmm.2018.3532Search in Google Scholar

20K. Liu, M. Zheng, R. Lu, J. Du, Q. Zhao, Z. Li, Y. Li and S. Zhang, The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review, Cancer Cell Int. 20 (2020) Article ID 213 (16 pages); https://doi.org/10.1186/s12935-020-01304-wSearch in Google Scholar

21S. Dalton, Cell cycle regulation of the human cdc2 gene, Embo J. 11(5) (1992) 1797–1804; https://doi.org/10.1002/j.1460-2075.1992.tb05231.xSearch in Google Scholar

22X. Yu, Q. Liang, W. Liu, L. Zhou, W. Li and H. Liu, Deguelin, an aurora B Kinase inhibitor, exhibits potent anti-tumor effect in human esophageal squamous cell carcinoma, EBioMedicine 26 (2017) 100–111; https://doi.org/10.1016/j.ebiom.2017.10.030Search in Google Scholar

23W. Li, X. Yu, X. Ma, L. Xie, Z. Xia, L. Liu, J. Wang, H. Zhou, X. Zhou, Y. Yang and H. Liu, Deguelin attenuates non-small cell lung cancer cell metastasis through inhibiting the CtsZ/FAK signaling pathway, Cell Signal. 50 (2018) 131–141; https://doi.org/10.1016/j.cellsig.2018.07.001Search in Google Scholar

24S. R. Boreddy and S. K. Srivastava, Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model, Oncogene 32(34) (2013) 3980–3991; https://doi.org/10.1038/onc.2012.413Search in Google Scholar

25J. Yang, J. Nie, X. Ma, Y. Wei, Y. Peng and X. Wei, Targeting PI3K in cancer: mechanisms and advances in clinical trials, Mol. Cancer 18(1) (2019) Article ID 26 (28 pages); https://doi.org/10.1186/s12943-019-0954-xSearch in Google Scholar

26B. D. Manning and L. C. Cantley, AKT/PKB signaling: navigating downstream, Cell 129(7) (2007) 1261–1274; https://doi.org/10.1016/j.cell.2007.06.009Search in Google Scholar

27G. M. Nitulescu, M. Van De Venter, G. Nitulescu, A. Ungurianu, P. Juzenas, Q. Peng, O. T. Olaru, D. Gradinaru, A. Tsatsakis, D. Tsoukalas, D. A. Spandidos and D. Margina, The Akt pathway in oncology therapy and beyond (Review), Int. J. Oncol. 53(6) (2018) 2319–2331; https://doi.org/10.3892/ijo.2018.4597Search in Google Scholar